TD Ameritrade Investment Management’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-38
Closed -$1K 597
2022
Q3
$1K Hold
38
﹤0.01% 549
2022
Q2
$1K Hold
38
﹤0.01% 574
2022
Q1
$2K Hold
38
﹤0.01% 598
2021
Q4
$2K Buy
+38
New +$1.72K ﹤0.01% 586

Other funds holding EBS

TD Ameritrade Investment Management's EBS Position: Q4 2022 in Review

TD Ameritrade Investment Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 38 shares — an estimated $1K sold.

TD Ameritrade Investment Management first reported a position in EBS in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • TD Ameritrade Investment Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 38 Emergent Biosolutions shares in Q4 2022, an estimated $1K.
  • TD Ameritrade Investment Management first reported a position in Emergent Biosolutions in Q4 2021 and held it in 4 quarters.
  • TD Ameritrade Investment Management's Emergent Biosolutions position peaked at $2K in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on TD Ameritrade Investment Management's 13F filing for Q4 2022, filed 9 Feb 2023.